Consensus NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
13.32 ^USD	-2.49%		+9.99%	-55.30%

Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE

Evolution of the Average Target: NovoCure Limited

Evolution of the Target Price: NovoCure Limited

Changes in Analyst Recommendations: NovoCure Limited

aa9893a4c617685694c51e63628.WhdsyPuJ2E5bC1Ba2mdmjYGmCM3iLhNgGehBR8XeEEI.EVZfgovA7joRfGUqmD40vNjOWb6wYGIKKZIqNoC6KCg7XTvwveGsKDZHMw~974db7981f05a63b2e72f99be89f2b53

Analysts' recommendations: NovoCure Limited

Jul. 25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
Jul. 25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
Jul. 24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
Jul. 08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	MT
Dec. 02	Evercore ISI Upgrades NovoCure to Outperform	MT
24-10-16	HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	MT
24-06-04	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
24-04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
24-04-03	Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	MT
24-02-23	Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	MT
23-10-26	Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	MT
23-08-29	Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	MT
23-08-28	HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	MT
23-08-28	Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	MT
23-08-08	Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	MT
23-08-04	SVB Securities Initiates NovoCure at Outperform With $51 Price Target	MT
23-07-31	Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-06-07	Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-05-16	Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
NOVOCURE LIMITED			+87.15%
PENUMBRA, INC.			-0.67%
MASIMO CORPORATION			+32.82%
GETINGE AB			+11.39%
ASAHI INTECC CO., LTD.			+10.05%
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.			+33.86%
APT MEDICAL INC.			+52.92%
INARI MEDICAL, INC.	-	-	-
CHEMOMETEC A/S			+24.11%
Average			+31.46%
Weighted average by Cap.			+21.65%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.32USD

Average target price

24.93USD

Spread / Average Target

+87.15%

High Price Target

42.00USD

Spread / Highest target

+215.32%

Low Price Target

14.50USD

Spread / Lowest Target

+8.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wells Fargo Securities
Wedbush
Ladenburg Thalmann
HC Wainwright
Leerink Partners
Evercore ISI
Piper Sandler
SVB Securities LLC
JPMorgan Chase
Truist Securities
Loop Capital
Oppenheimer
Mizuho Securities
Northland Securities
J.P. Morgan Chase